Genome-wide analysis of LPS-induced inflammatory response in the rat ventral hippocampus: Modulatory activity of the antidepressant agomelatine

References

• Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A. 2009. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 26:607–611.
   PubMed Web of Science ®Google Scholar
• Anisman H, Merali Z, Hayley S. 2008. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol. 85:1–74.
   PubMed Web of Science ®Google Scholar
• Bach TL, Chen QM, Kerr WT, Wang Y, Lian L, Choi JK, Wu D, Kazanietz MG, Koretzky GA, Zigmond S, et al. 2007. Phospholipase cbeta is critical for T cell chemotaxis. J Immunol. 179:2223–2227.
   PubMed Web of Science ®Google Scholar
• Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G. 2001. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol. 22:147–184.
   PubMed Web of Science ®Google Scholar
• Berge LI, Riise T. 2015. Comorbidity between type 2 diabetes and depression in the adult population: directions of the association and its possible pathophysiological mechanisms. Int J Endocrinol. 2015:164760.
   PubMedGoogle Scholar
• Bluthe RM, Dantzer R, Kelley KW. 1992. Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res. 573:318–320.
   PubMed Web of Science ®Google Scholar
• Bolstad BM, Irizarry RA, Astrand M, Speed TP. 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 19:185–193.
   PubMed Web of Science ®Google Scholar
• Boulle F, Velthuis H, Koedam K, Steinbusch HW, van den Hove DL, Kenis G, Gabriel C, Mocaer E, Franc B, Rognan D, et al. 2016. Behavioral and neurochemical characterization of TrkB-dependent mechanisms of agomelatine in glucocorticoid receptor-impaired mice. Eur Neuropsychopharmacol. 26:65–77.
   PubMed Web of Science ®Google Scholar
• Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, et al. 2011. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 9:90.
   PubMed Web of Science ®Google Scholar
• Brunello N, Alboni S, Capone G, Benatti C, Blom JM, Tascedda F, Kriwin P, Mendlewicz J. 2006. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol. 21:219–225.
   PubMed Web of Science ®Google Scholar
• Calabrese F, Molteni R, Gabriel C, Mocaer E, Racagni G, Riva MA. 2011. Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine. Psychopharmacology (Berlin). 215:267–275.
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. 2012. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs. 17:105–126.
   PubMed Web of Science ®Google Scholar
• Corti C, Battaglia G, Molinaro G, Riozzi B, Pittaluga A, Corsi M, Mugnaini M, Nicoletti F, Bruno V. 2007. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci. 27:8297–8308.
   PubMed Web of Science ®Google Scholar
• Cuccurazzu B, Bortolotto V, Valente MM, Ubezio F, Koverech A, Canonico PL, Grilli M. 2013. Upregulation of mGlu2 receptors via NF-κB p65 acetylation is involved in the Proneurogenic and antidepressant effects of acetyl-L-carnitine. Neuropsychopharmacology. 38:2220–2230.
   PubMed Web of Science ®Google Scholar
• Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. 2008. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 9:46–56.
   PubMed Web of Science ®Google Scholar
• de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. 2010. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 9:628–642.
   PubMed Web of Science ®Google Scholar
• de Mello AH, Souza LD, Cereja AC, Schraiber RB, Florentino D, Martins MM, Petronilho F, Quevedo J, Rezin GT. 2015. Effect of subchronic administration of agomelatine on brain energy metabolism and oxidative stress parameters in rats. Psychiatry Clin Neurosci. 70:159–166.
   PubMed Web of Science ®Google Scholar
• Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL. 2010. A meta-analysis of cytokines in major depression. Biol Psychiatry. 67:446–457.
   PubMed Web of Science ®Google Scholar
• Duman RS, Monteggia LM. 2006. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 59:1116–1127.
   PubMed Web of Science ®Google Scholar
• Fanselow MS, Dong HW. 2010. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron. 65:7–19.
   PubMed Web of Science ®Google Scholar
• Frenois F, Moreau M, O'Connor J, Lawson M, Micon C, Lestage J, Kelley KW, Dantzer R, Castanon N. 2007. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology. 32:516–531.
   PubMed Web of Science ®Google Scholar
• Gray AL, Hyde TM, Deep-Soboslay A, Kleinman JE, Sodhi MS. 2015. Sex differences in glutamate receptor gene expression in major depression and suicide. Mol Psychiatry. 20:1139.
   PubMed Web of Science ®Google Scholar
• Haroon E, Raison CL, Miller AH. 2012. Psychoneuroimmun-ology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 37:137–162.
   PubMed Web of Science ®Google Scholar
• Heinisch S, Kirby LG. 2010. SDF-1alpha/CXCL12 enhances GABA and glutamate synaptic activity at serotonin neurons in the rat dorsal raphe nucleus. Neuropharmacology. 58:501–514.
   PubMed Web of Science ®Google Scholar
• Howren MB, Lamkin DM, Suls J. 2009. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 71:171–186.
   PubMed Web of Science ®Google Scholar
• Huang Y, Coupland NJ, Lebel RM, Carter R, Seres P, Wilman AH, Malykhin NV. 2013. Structural changes in hippocampal subfields in major depressive disorder: a high-field magnetic resonance imaging study. Biol Psychiatry. 74:62–68.
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264.
   PubMed Web of Science ®Google Scholar
• Janssen DG, Caniato RN, Verster JC, Baune BT. 2010. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol. 25:201–215.
   PubMed Web of Science ®Google Scholar
• Jiang B, Wang F, Yang S, Fang P, Deng ZF, Xiao JL, Hu ZL, Chen JG. 2014. SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway. Int J Neuropsychopharmacol. 18:6.
   Web of Science ®Google Scholar
• Konsman JP, Kelley K, Dantzer R. 1999. Temporal and spatial relationships between lipopolysaccharide-induced expression of Fos, interleukin-1beta and inducible nitric oxide synthase in rat brain. Neuroscience. 89:535–548.
   PubMed Web of Science ®Google Scholar
• Macchi F, Homberg JR, Calabrese F, Zecchillo C, Racagni G, Riva MA, Molteni R. 2013. Altered inflammatory responsiveness in serotonin transporter mutant rats. J Neuroinflammation. 10:116.
   PubMed Web of Science ®Google Scholar
• Malykhin NV, Carter R, Seres P, Coupland NJ. 2010. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J Psychiatry Neurosci. 35:337–343.
   PubMed Web of Science ®Google Scholar
• Malykhin NV, Coupland NJ. 2015. Hippocampal neuroplasticity in major depressive disorder. Neuroscience. 309:200–213.
   PubMed Web of Science ®Google Scholar
• Miller AH, Raison CL. 2015. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 16:22–34.
   Web of Science ®Google Scholar
• Molteni R, Macchi F, Zecchillo C, Dell'agli M, Colombo E, Calabrese F, Guidotti G, Racagni G, Riva MA. 2013. Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine. Eur Neuropsychopharmacol. 23:1645–1655.
   PubMed Web of Science ®Google Scholar
• Nagasawa T. 2014. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med (Berlin). 92:433–439.
   PubMed Web of Science ®Google Scholar
• Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, Battaglia G, Mathe AA, Pittaluga A, Lionetto L, et al. 2013. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci USA. 110:4804–4809.
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca P, Boyer PA, Mocaer E. 2003. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology. 28:694–703.
   PubMed Web of Science ®Google Scholar
• Pevet P. 2003. Melatonin in animal models. Dialogues Clin Neurosci. 5:343–352.
   PubMedGoogle Scholar
• Raison CL, Capuron L, Miller AH. 2006. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27:24–31.
   PubMed Web of Science ®Google Scholar
• Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. 2013. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 70:31–41.
   PubMed Web of Science ®Google Scholar
• Rantamaki T, Hendolin P, Kankaanpaa A, Mijatovic J, Piepponen P, Domenici E, Chao MV, Mannisto PT, Castren E. 2007. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology. 32:2152–2162.
   PubMed Web of Science ®Google Scholar
• Reaux-Le Goazigo A, Van Steenwinckel J, Rostene W, Melik Parsadaniantz S. 2013. Current status of chemokines in the adult CNS. Prog Neurobiol. 104:67–92.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Korkmaz A, Paredes SD, Manchester LC, Tan DX. 2008. Melatonin reduces oxidative/nitrosative stress due to drugs, toxins, metals, and herbicides. Neuro Endocrinol Lett. 29:609–613.
   PubMed Web of Science ®Google Scholar
• Reus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, Kapczinski F, Quevedo J. 2015. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience. 300:141–154.
   PubMed Web of Science ®Google Scholar
• Rossetti AC, Papp M, Gruca P, Paladini MS, Racagni G, Riva MA, Molteni R. 2016. Stress-induced anhedonia is associated with the activation of the inflammatory system in the rat brain: restorative effect of pharmacological intervention. Pharmacol Res. 103:1–12.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Treccani G, Popoli M. 2012. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 62:63–77.
   PubMed Web of Science ®Google Scholar
• Shyu WC, Lin SZ, Yen PS, Su CY, Chen DC, Wang HJ, Li H. 2008. Stromal cell-derived factor-1 alpha promotes neuroprotection, angiogenesis, and mobilization/homing of bone marrow-derived cells in stroke rats. J Pharmacol Exp Ther. 324:834–849.
   PubMed Web of Science ®Google Scholar
• Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. 2015. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol. 25:1532–1543.
   PubMed Web of Science ®Google Scholar
• Sukoff Rizzo SJ, Neal SJ, Hughes ZA, Beyna M, Rosenzweig-Lipson S, Moss SJ, Brandon NJ. 2012. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl Psychiatry. 2:e199.
   PubMed Web of Science ®Google Scholar
• Taylor DL, Jones F, Kubota ES, Pocock JM. 2005. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J Neurosci. 25:2952–2964.
   PubMed Web of Science ®Google Scholar
• van Heesch F, Prins J, Konsman JP, Westphal KG, Olivier B, Kraneveld AD, Korte SM. 2013. Lipopolysaccharide-induced anhedonia is abolished in male serotonin transporter knockout rats: an intracranial self-stimulation study. Brain Behav Immun. 29:98–103.
   PubMed Web of Science ®Google Scholar
• Williamson LL, Bilbo SD. 2013. Chemokines and the hippocampus: a new perspective on hippocampal plasticity and vulnerability. Brain Behav Immun. 30:186–194.
   PubMed Web of Science ®Google Scholar
• Wohleb ES, Franklin T, Iwata M, Duman RS. 2016. Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci. 17:497–511.
   PubMed Web of Science ®Google Scholar
• Wu TH, Lin CH. 2008. IL-6 mediated alterations on immobile behavior of rats in the forced swim test via ERK1/2 activation in specific brain regions. Behav Brain Res. 193:183–191.
   PubMed Web of Science ®Google Scholar
• Yang YR, Follo MY, Cocco L, Suh PG. 2013. The physiological roles of primary phospholipase C. Adv Biol Regul. 53:232–241.
   PubMedGoogle Scholar
• Yirmiya R. 1996. Endotoxin produces a depressive-like episode in rats. Brain Res. 711:163–174.
   PubMed Web of Science ®Google Scholar
• Zhu CB, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA. 2010. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology. 35:2510–2520.
   PubMed Web of Science ®Google Scholar